Precision medicine: The future in diabetes care?

Diabetes Research and Clinical Practice

Volumn 117, Issue , 2016, Pages 12-21

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Patient centred therapy; Personalized medicine; Pharmacogenetics; Pharmacogenomics; Precision medicine; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; BIOLOGICAL MARKER; C PEPTIDE; CANAGLIFLOZIN; CYTOCHROME P450; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; MEGLITINIDE DERIVATIVE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL OBESITY; AFRICAN AMERICAN; AGE DISTRIBUTION; ALLELE; ANTIDIABETIC ACTIVITY; ASIAN; BODY MASS; BODY WEIGHT DISORDER; BODY WEIGHT GAIN; BODY WEIGHT LOSS; BOLUS INJECTION; CELL FUNCTION; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY RISK; CYP2C8 GENE; DIABETES CARE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG TRANSPORT; DRUG TREATMENT FAILURE; EDEMA; ESTIMATED GLOMERULAR FILTRATION RATE; EUROPEAN AMERICAN; FASTING HYPERGLYCAEMIA; FASTING HYPERGLYCEMIA; GASTROINTESTINAL INTOLERANCE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENE MUTATION; GENE TARGETING; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOSITY; HNF1A GENE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; IRS 1 GENE; LIVER TOXICITY; LPL GENE; MARKER GENE; METABOLIC SYNDROME X; METABOLOMICS; METAGENOMICS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OATP1B1 GENE; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; POSTPRANDIAL HYPERGLYCEMIA; PPAR GAMMA GENE; PRACTICE GUIDELINE; PRESCRIPTION; PROTEIN FUNCTION; PROTEIN TARGETING; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SGLT2 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLC22A1 GENE; TCF7L2 GENE; UNSPECIFIED SIDE EFFECT; DIABETES MELLITUS, TYPE 2; GENETICS; PHARMACOGENETICS;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PHARMACOGENETICS; PRECISION MEDICINE;

EID: 84981201738     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.04.033     Document Type: Review

References (83)

1. Cantrell, R.A., Alatorre, C.I., Davis, E.J., Zarotsky, V., Le Nestour, E., Carter, G.C., et al. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diabetes Obes Metab 12 (2010), 845–857.
2. Leslie, R.D., Palmer, J., Schloot, N.C., Lernmark, A., Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 59 (2016), 13–20.
3. Kaul, N., Ali, S., Genes, genetics, and environment in type 2 diabetes: implication in personalized medicine. DNA Cell Biol 35 (2016), 1–12.
4. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetologia 58 (2015), 429–442.
5. Garber, A.J., Abrahamson, M.J., Barzilay, J.I., Blonde, L., Bloomgarden, Z.T., Bush, M.A., et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summary. Endocr Pract 22 (2016), 84–113.
6. Raz, I., Riddle, M.C., Rosenstock, J., Buse, J.B., Inzucchi, S.E., Home, P.D., et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 36 (2013), 1779–1788.
7. Scheen, A.J., Lefebvre, P.J., Oral antidiabetic agents. A guide to selection. Drugs 55 (1998), 225–236.
8. Kleinberger, J.W., Pollin, T.I., Personalized medicine in diabetes mellitus: current opportunities and future prospects. Ann N Y Acad Sci 1346 (2015), 45–56.
9. Smith, R.J., Nathan, D.M., Arslanian, S.A., Groop, L., Rizza, R.A., Rotter, J.I., Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 95 (2010), 1566–1574.
10. Maruthur, N.M., Gribble, M.O., Bennett, W.L., Bolen, S., Wilson, L.M., Balakrishnan, P., et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care 37 (2014), 876–886.
11. Scheen, A.J., A review of gliptins for 2014. Exp Opin Pharmacother 16 (2015), 43–62.
12. Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
13. Del Prato, S., LaSalle, J., Matthaei, S., Bailey, C.J., Global Partnership for Effective Diabetes M, Tailoring treatment to the individual in type 2 diabetes practical guidance from the global partnership for effective diabetes management. Int J Clin Pract 64 (2010), 295–304.
14. Bailey, C.J., Aschner, P., Del Prato, S., LaSalle, J., Ji, L., Matthaei, S., et al. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res 10 (2013), 397–409.
15. Ceriello, A., Gallo, M., Candido, R., De Micheli, A., Esposito, K., Gentile, S., et al. Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med 7 (2014), 129–136.
16. Ismail-Beigi, F., Moghissi, E., Tiktin, M., Hirsch, I.B., Inzucchi, S.E., Genuth, S., Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154 (2011), 554–559.
17. Scheen, A.J., Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 14 (2015), 505–524.
18. Monami, M., Cremasco, F., Lamanna, C., Marchionni, N., Mannucci, E., Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 27 (2011), 362–372.
19. McGill, J.B., Vlajnic, A., Knutsen, P.G., Recklein, C., Rimler, M., Fisher, S.J., Effect of gender on treatment outcomes in type 2 diabetes mellitus. Diabetes Res Clin Pract 102 (2013), 167–174.
20. Scheen, A.J., Paquot, N., Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 39 (2013), 179–190.
21. Scheen, A.J., Van Gaal, L.F., Combating the dual burden : therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2 (2014), 911–922.
22. Van Gaal, L., Scheen, A., Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 38 (2015), 1161–1172.
23. Williams, L.K., Padhukasahasram, B., Ahmedani, B.K., Peterson, E.L., Wells, K.E., Gonzalez Burchard, E., et al. Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 99 (2014), 3160–3168.
24. Kim, Y.G., Hahn, S., Oh, T.J., Kwak, S.H., Park, K.S., Cho, Y.M., Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56 (2013), 696–708.
25. Scheen, A.J., Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 54 (2015), 1–21.
26. Scheen, A.J., Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet 54 (2015), 691–708.
27. Scheen, A.J., Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol 10 (2014), 839–857.
28. Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006), 2297–2307.
29. Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
30. Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
31. Scheen, A.J., Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?. Nature Clin Pract Endocrinol Metab 4 (2008), 260–261.
32. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
33. Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
34. Group UKPDS, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 854–865.
35. Scheen, A.J., Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 98 (2012), 175–186.
36. Engelbrechtsen, L., Andersson, E., Roepstorff, S., Hansen, T., Vestergaard, H., Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes. Pharmacogenet Genomics 25 (2015), 475–484.
37. Scheen, A.J., Castillo, M.J., Lefebvre, P.J., Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 22 (1996), 397–406.
38. Saisho, Y., Importance of beta cell function for the treatment of type 2 diabetes. J Clin Med 3 (2014), 923–943.
39. Jones, A.G., Hattersley, A.T., The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30 (2013), 803–817.
40. Jones, A.G., McDonald, T.J., Shields, B.M., Hill, A.V., Hyde, C.J., Knight, B.A., et al. Markers of beta-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 39 (2016), 250–257.
41. Pearson, E., Personalized medicine in diabetes: the role of ’omics’ and biomarkers. Diabet Med, 2016, 10.1111/dme.13075 [Epub ahead of print].
42. Mamza, J., Mehta, R., Donnelly, R., Idris, I., Determinants of glycemic response to add-on therapy with a dipeptidyl peptidase-4 inhibitor: a retrospective cohort study using a United Kingdom primary care database. Diabetes Technol Ther 18 (2016), 85–92.
43. Nishimura, T., Meguro, S., Sekioka, R., Tanaka, K., Saisho, Y., Irie, J., et al. C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes. Diabetes Res Clin Pract 108 (2015), 441–447.
44. Nakamura, A., Terauchi, Y., Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes. Endocr J 60 (2013), 45–49.
45. Mooradian, A., Chehade, J.M., Mooradian, A.D., Advantages and pitfalls of antihyperglycemic combination pills as first-line therapy in the management of type 2 diabetes. Am J Ther, 2015 [Epub ahead of print].
46. Qiu, Y., Li, Q., Tang, J., Fan, C.P., Li, Z., Apecechea, M., et al. Why physicians do not initiate dual therapy as recommended by AACE guidelines: a survey of clinicians in the United States. Diabetes Res Clin Pract 108 (2015), 456–465.
47. DeFronzo, R.A., Stonehouse, A.H., Han, J., Wintle, M.E., Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 27 (2010), 309–317.
48. Rosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38 (2015), 376–383.
49. Scheen, A.J., Schmitt, H., Jiang, H.H., Ivanyi, T., Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: Response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity. Diabetes Metab 41 (2015), 216–222.
50. Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 (2012), 728–742.
51. Mannino, G.C., Sesti, G., Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data. Mol Diagn Ther 16 (2012), 285–302.
52. van Leeuwen, N., Swen, J.J., Guchelaar, H.J., t Hart, L.M., The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. Clin Pharmacokinet 52 (2013), 833–854.
53. Hara, K., Kadowaki, T., Odawara, M., Genes associated with diabetes: potential for novel therapeutic targets?. Expert Opin Ther Targets 20 (2016), 255–267.
54. Avery, P., Mousa, S.S., Mousa, S.A., Pharmacogenomics in type II diabetes mellitus management: steps toward personalized medicine. Pharmgenomics Pers Med 2 (2009), 79–91.
55. Semiz, S., Dujic, T., Causevic, A., Pharmacogenetics and personalized treatment of type 2 diabetes. Biochem Med (Zagreb) 23 (2013), 154–171.
56. Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B., Brockmoller, J., Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 44 (2005), 1209–1225.
57. Shu, Y., Sheardown, S.A., Brown, C., Owen, R.P., Zhang, S., Castro, R.A., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117 (2007), 1422–1431.
58. Dujic, T., Zhou, K., Donnelly, L.A., Tavendale, R., Palmer, C.N., Pearson, E.R., Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes 64 (2015), 1786–1793.
59. Dujic, T., Causevic, A., Bego, T., Malenica, M., Velija-Asimi, Z., Pearson, E.R., et al. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with type 2 diabetes. Diabet Med 33 (2016), 511–514.
60. GoDarts, Group UDPS, Wellcome Trust Case Control C, Zhou, K., Bellenguez, C., Spencer, C.C., et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43 (2011), 117–120.
61. Reitman, M.L., Schadt, E.E., Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117 (2007), 1226–1229.
62. Scheen, A.J., Personalising metformin therapy: a clinician's perspective. Lancet Diabetes Endocrinol 2 (2014), 442–444.
63. Shepherd, M., Shields, B., Ellard, S., Rubio-Cabezas, O., Hattersley, A.T., A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 26 (2009), 437–441.
64. Pearson, E.R., Donnelly, L.A., Kimber, C., Whitley, A., Doney, A.S., McCarthy, M.I., et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 56 (2007), 2178–2182.
65. Holstein, A., Hahn, M., Korner, A., Stumvoll, M., Kovacs, P., TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet, 12, 2011, 30.
66. Sesti, G., Marini, M.A., Cardellini, M., Sciacqua, A., Frontoni, S., Andreozzi, F., et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 27 (2004), 1394–1398.
67. Loganadan, N.K., Huri, H.Z., Vethakkan, S.R., Hussein, Z., Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. Pharmacogenomics J, 2016, 10.1038/tpj.2015.95 [Epub ahead of print].
68. Scheen, A.J., Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 46 (2007), 93–108.
69. Kalliokoski, A., Neuvonen, P.J., Niemi, M., SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol 107 (2010), 775–781.
70. Scheen, A.J., Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 46 (2007), 1–12.
71. Kawaguchi-Suzuki, M., Frye, R.F., Current clinical evidence on pioglitazone pharmacogenomics. Front Pharmacol, 4, 2013, 147.
72. Stage, T.B., Christensen, M.M., Feddersen, S., Beck-Nielsen, H., Brosen, K., The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARgamma on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenet Genomics 23 (2013), 219–227.
73. Della-Morte, D., Palmirotta, R., Rehni, A.K., Pastore, D., Capuani, B., Pacifici, F., et al. Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. Pharmacogenomics 15 (2014), 2063–2082.
74. Bluher, M., Lubben, G., Paschke, R., Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 26 (2003), 825–831.
75. Wang, G., Wang, X., Zhang, Q., Ma, Z., Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus. Int J Clin Pract 61 (2007), 552–557.
76. Yang, H., Ye, E., Si, G., Chen, L., Cai, L., Ye, C., et al. Adiponectin gene polymorphism rs2241766 T/G is associated with response to pioglitazone treatment in type 2 diabetic patients from southern China. PLoS One, 9, 2014, e112480.
77. Scheen, A.J., Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12 (2010), 648–658.
78. Aquilante, C.L., Wempe, M.F., Sidhom, M.S., Kosmiski, L.A., Predhomme, J.A., Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Eur J Clin Pharmacol 69 (2013), 1401–1409.
79. Su, H., Boulton, D.W., Barros, A. Jr., Wang, L., Cao, K., Bonacorsi, S.J. Jr, et al. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. Drug Metab Dispos 40 (2012), 1345–1356.
80. Zimdahl, H., Ittrich, C., Graefe-Mody, U., Boehm, B.O., Mark, M., Woerle, H.J., et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia 57 (2014), 1869–1875.
81. Amblee, A., Patient profiling in diabetes and role of canagliflozin. Pharmgenomics Pers Med 7 (2014), 367–377.
82. Francke, S., Mamidi, R.N., Solanki, B., Scheers, E., Jadwin, A., Favis, R., et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol 55 (2015), 1061–1072.
83. Hoeben, E., De Winter, W., Neyens, M., Devineni, D., Vermeulen, A., Dunne, A., Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 55 (2016), 209–223.